Cytotoxic effects of camptothecin and cisplatin combined with tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL) in a model of primary culture of non-small cell lung cancer

Anticancer Research

Volumn 29, Issue 8, 2009, Pages 2905-2911

  Frese, Steffen ^a   Schüller, Alexandra ^a   Frese Schaper, Manuela ^a   Gugger, Mathias ^b   Schmid, Ralph A ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Apoptosis; Non small cell lung cancer; Primary culture; Tumor necrosis factor related apoptosis inducing ligand

Indexed keywords

CAMPTOTHECIN; CASPASE 3; CASPASE 6; CISPLATIN; DEATH RECEPTOR 4; DEATH RECEPTOR 5; LAMIN A; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR 3;

ANALYSIS OF VARIANCE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; POST HOC ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; CELLS, CULTURED; CISPLATIN; COMBINED MODALITY THERAPY; HUMANS; IMMUNOBLOTTING; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 68549136613     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin 58: 71-96, 2008.
2. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M and Boyle P: Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18: 581-592, 2007.
3. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA and Goodwin RG: Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3: 673-682, 1995. (Pubitemid 26091143)
4. Sprick MR, Weigand MA, Rieser E, Rauch CT, Juo P, Blenis J, Krammer PH and Walczak H: FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 12: 599-609, 2000.
5. Griffithand TS and Lynch DH: TRAIL: a molecule with multiple receptors and control mechanisms. Curr Opin Immunol 10: 559-563, 1998.
6. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC and Lynch DH: Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5: 157-163, 1999. (Pubitemid 29068521)
7. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z and Schwall RH: Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104: 155-162, 1999.
8. Jo M, Kim TH, Seol DW, Esplen JE, Dorko K, Billiar TR and Strom SC: Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 6: 564-567, 2000. (Pubitemid 30305907)
9. Nesterov A, Ivashchenko Y and Kraft AS: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) triggers apoptosis in normal prostate epithelial cells. Oncogene 21: 1135-1140, 2002. (Pubitemid 34174527)
10. Takeda K, Kojima Y, Ikejima K, Harada K, Yamashina S, Okumura K, Aoyama T, Frese S, Ikeda H, Haynes NM, Cretney E, Yagita H, Sueyoshi N, Sato N, Nakanuma Y and Smyth MJ: Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease. Proc Natl Acad Sci USA 105: 10895-10900, 2008.
11. Frese S, Brunner T, Gugger M, Uduehi A and Schmid RA: Enhancement of Apo2L/TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-induced apoptosis in non-small cell lung cancer cell lines by chemotherapeutic agents without correlation to the expression level of cellular protease caspase-8 inhibitory protein. J Thorac Cardiovasc Surg 123: 168-174, 2002.
12. Frese S, Pirnia F, Miescher D, Krajewski S, Borner MM, Reed JC and Schmid RA: PG490-mediated sensitization of lung cancer cells to Apo2L/TRAIL-induced apoptosis requires activation of ERK2. Oncogene 22: 5427-5435, 2003. (Pubitemid 37072197)
13. Frese S, Frese-Schaper M, Andres AC, Miescher D, Zumkehr B, and Schmid RA: Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5. Cancer Res 66: 5867-5874, 2006. (Pubitemid 43927141)
14. Pirnia F, Frese S, Gloor B, Hotz MA, Luethi A, Gugger M, Betticher DC and Borner MM: Ex vivo assessment of chemotherapy-induced apoptosis and associated molecular changes in patient tumor samples. Anticancer Res 26: 1765-1772, 2006. (Pubitemid 43989430)
15. Frese S, Schaper M, Kuster JR, Miescher D, Jaattela M, Buehler T and Schmid RA: Cell death induced by down-regulation of heat-shock protein 70 in lung cancer cell lines is p53-independent and does not require DNA cleavage. J Thorac Cardiovasc Surg 126: 748-754, 2003. (Pubitemid 37151959)
16. Orth K, Chinnaiyan AM, Garg M, Froelich CJ and Dixit VM: The CED-3/ICE-like protease Mch2 is activated during apoptosis and cleaves the death substrate lamin A. J Biol Chem 271: 16443-16446, 1996. (Pubitemid 26238991)
17. Oikonomou E, Kothonidis K, Taoufik E, Probert E, Zografos G, Nasioulas G, Andera L and Pintzas A: Newly established tumourigenic primary human colon cancer cell lines are sensitive to TRAIL-induced apoptosis in vitro and in vivo. Br J Cancer 97: 73-84, 2007. (Pubitemid 47012093)
18. Nguyen T, Zhang XD and Hersey P: Relative resistance of fresh isolates of melanoma to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. Clin Cancer Res 7: 966s-973s, 2001. (Pubitemid 33600952)
19. Meurette O, Fontaine A, Rebillard A, Le Moigne G, Lamy T, Lagadic-Gossmann D and Dimanche-Boitrel MT: Cytotoxicity of TRAIL/anticancer drug combinations in human normal cells. Ann N Y Acad Sci 1090: 209-216, 2006. (Pubitemid 47092125)
20. Gliniak B and Le T: Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11. Cancer Res 59: 6153-6158, 1999. (Pubitemid 30035636)
21. Sugamura K, Gibbs JF, Belicha-Villanueva A, Andrews C, Repasky EA and Hylander BL: Synergism of CPT-11 and Apo2L/TRAIL against two differentially sensitive human colon tumor xenografts. Oncology 74: 188-197, 2008.
22. Xiang H, Fox JA, Totpal K, Aikawa M, Dupree K, Sinicropi D, Lowe J and Escandon E: Enhanced tumor killing by Apo2L/TRAIL and CPT-11 co-treatment is associated with p21 cleavage and differential regulation of Apo2L/TRAIL ligand and its receptors. Oncogene 21: 3611-3619, 2002. (Pubitemid 34587693)